3 US Penny Stocks With Market Caps Over $30M To Watch

After two days of record highs, the U.S. stock market saw a decline with major indices like the Dow Jones and Nasdaq posting losses. In such fluctuating conditions, investors often look for opportunities in various segments of the market, including penny stocks. Although considered an outdated term, penny stocks still represent smaller or newer companies that can offer both affordability and growth potential when backed by strong financials.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)	$3.08	$132.89M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.78	$85.54M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.44	$47.85M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.2695	$9.57M	★★★★★★
PHX Minerals (NYSE:PHX)	$4.20	$156.67M	★★★★★☆
Smith Micro Software (NasdaqCM:SMSI)	$1.43	$24.83M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.8696	$79.96M	★★★★★☆
BAB (OTCPK:BABB)	$0.83	$6.31M	★★★★★☆
Lifetime Brands (NasdaqGS:LCUT)	$4.95	$110.78M	★★★★★☆

Click here to see the full list of 712 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Aadi Bioscience (NasdaqCM:AADI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers involving mTOR pathway gene alterations, with a market cap of $70.74 million.

Operations: The company generates revenue of $25.07 million from its segment focused on the development and commercialization of proprietary therapeutics.

Market Cap: $70.74M

Aadi Bioscience, Inc., with a market cap of US$70.74 million, is navigating significant strategic shifts amid its unprofitable status and volatile share price. The recent appointment of Dr. David Dornan as Chief Scientific Officer underscores the company's focus on advancing its portfolio of antibody-drug conjugates (ADCs). Aadi's strategic plan includes selling FYARRO® for US$100 million and acquiring ADC assets from WuXi Biologics, supported by a US$100 million private placement financing. Despite financial challenges, Aadi remains debt-free with sufficient short-term assets to cover liabilities and an experienced board guiding these transformative efforts.

• Unlock comprehensive insights into our analysis of Aadi Bioscience stock in this financial health report.
• Understand Aadi Bioscience's earnings outlook by examining our growth report.

PodcastOne (NasdaqCM:PODC)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: PodcastOne, Inc. operates as a podcast platform and publisher with a market cap of $50.54 million.

Operations: The company generates $49.73 million in revenue from its Internet Information Providers segment.

Market Cap: $50.54M

PodcastOne, Inc., with a market cap of US$50.54 million, is navigating the competitive podcasting landscape amid its unprofitable status. Recent developments include a renewed partnership with Kailyn Lowry and an agreement with ART19 LLC for enhanced monetization opportunities, ensuring a minimum guarantee of US$15 million over three years. The company reported third-quarter sales of US$12.71 million and reduced net losses compared to the previous year. Despite high share price volatility and limited cash runway, PodcastOne's revenue is projected to grow by 17% annually as it seeks acquisitions to bolster growth prospects in this dynamic sector.

• Navigate through the intricacies of PodcastOne with our comprehensive balance sheet health report here.
• Gain insights into PodcastOne's future direction by reviewing our growth report.

Investview (OTCPK:INVU)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Investview, Inc., through its subsidiaries, offers financial products and services focused on financial education, digital assets, and related technology for individuals, with a market cap of $38.21 million.

Operations: The company generates revenue of $58.45 million from its online financial information provider segment.

Market Cap: $38.21M

Investview, Inc., with a market cap of US$38.21 million, has recently become profitable, marking a significant turnaround from its previous financial struggles. The company's short-term assets of US$30.8 million exceed both its short and long-term liabilities, indicating strong liquidity. Despite this progress, the company faced a regulatory challenge with the SEC concerning past unregistered investment contracts related to bitcoin mining equipment sales, resulting in a US$375,000 penalty settlement. While INVU's debt is well-covered by operating cash flow and interest payments are manageable at 4.5 times coverage by EBIT, share price volatility remains high at 25%.

• Click here to discover the nuances of Investview with our detailed analytical financial health report.
• Gain insights into Investview's historical outcomes by reviewing our past performance report.

Summing It All Up

• Navigate through the entire inventory of 712 US Penny Stocks here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com